Tru Niagen — Nicotinamide Riboside (NIAGEN)
The patented NR supplement from ChromaDex — the most clinically-trialed NAD+ precursor, $50-90/month.
The NAD+ precursor that came with the patent and the published trials — ChromaDex's NIAGEN is the most-studied NR on the market, sold direct as Tru Niagen.
If NMN gets the Sinclair-podcast attention, NR (nicotinamide riboside) gets the trial publications. ChromaDex's patented NIAGEN compound has been the subject of ~30+ peer-reviewed human trials — including studies tracking blood NAD+ levels, mitochondrial markers, and cardiovascular biomarkers.
The NR vs NMN debate is one of the most contested arguments in the longevity supplement category. Both convert to NAD+ via different pathways. NMN advocates argue for direct NAD+ precursor dosing. NR advocates argue NIAGEN has the actual published human trials. What's clear: NR has a longer commercial history (since ~2013), more institutional research, and FDA NDI / GRAS notification — none of which NMN currently has.
Where it wins: published evidence at the dose sold. ChromaDex has funded or partnered on ~30+ human trials of NIAGEN. The 300mg dose at ~$50/mo subscribed lands in same price range as Mitopure but with longer evidence base. Sold in CVS, Mayo Clinic research partnerships — institutional credibility most longevity supplements lack.
Where it loses: marketing is conservative to the point of being inaccessible. Tru Niagen messaging is regulatory-compliant ("supports cellular energy") rather than mechanistic, which makes it harder for consumers to understand why they'd buy it vs NMN. Brand has been less effective than NOVOS or Timeline at communicating to longevity-pro buyers.
FDA / regulatory context: NR has both NDI and GRAS status — credentials NMN currently lacks following the FDA's 2022 reclassification of NMN. NR can be sold and shipped freely; NMN exists in a gray zone in the U.S. market.
Evidence-first buyers who prioritize the most-studied NAD+ precursor with FDA NDI / GRAS status, and longevity-pro buyers who want institutional brand credibility.
You specifically want NMN (different precursor pathway), you're tracking aggressive Sinclair-style protocols, or you find the conservative messaging insufficient.
Pros
- Patented NIAGEN compound — exclusive to Tru Niagen
- ~30+ peer-reviewed human trials — most-studied NAD+ precursor available
- FDA NDI and GRAS regulatory status — clearest legal standing
- ChromaDex parent publicly traded (NASDAQ: CDXC) — institutional accountability
- Mayo Clinic research partnership
- Sold in CVS retail nationwide
- 300mg dose matches the dose used in most published trials
- Multi-bottle and subscribe & save brings per-month to ~$50
- Impact network affiliate program with 30-day cookie
- 600mg "Pro" tier for buyers wanting trial-protocol dosing
Cons
- Conservative marketing language undersells mechanism vs NMN competitors
- Many longevity-pro buyers default to NMN despite NR having stronger published evidence
- $50-90/mo at 300mg — 600mg "Pro" tier nearly doubles cost
- No "Sinclair effect" — NR doesn't carry same celebrity-researcher endorsement as NMN
- Single-ingredient product — buyers without foundational stack should layer it later, not first
Specifications
Most often compared with
Tru Niagen — Nicotinamide Riboside (NIAGEN)
$50–$90/mo · Verified 2026-05-03
View at Tru Niagen →